QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$12.84
+0.32 (+2.56 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.47
Now: $12.84
$12.98
50-Day Range
$10.26
MA: $11.85
$14.55
52-Week Range
$5.63
Now: $12.84
$18.35
Volume438,905 shs
Average Volume701,739 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Read More
Athenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$101.23 million
Book Value$2.15 per share

Profitability

Net Income$-123,750,000.00

Miscellaneous

Employees575
Market Cap$1.05 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$12.84
+0.32 (+2.56 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Athenex (NASDAQ:ATNX) Frequently Asked Questions

How has Athenex's stock price been impacted by Coronavirus?

Athenex's stock was trading at $9.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATNX stock has increased by 32.9% and is now trading at $12.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Athenex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Athenex
.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex Inc (NASDAQ:ATNX) issued its earnings results on Thursday, August, 6th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.19. The business had revenue of $40.17 million for the quarter, compared to analysts' expectations of $21.20 million. Athenex had a negative net margin of 82.63% and a negative return on equity of 73.35%.
View Athenex's earnings history
.

What price target have analysts set for ATNX?

4 equities research analysts have issued 1-year target prices for Athenex's stock. Their forecasts range from $23.00 to $33.00. On average, they expect Athenex's share price to reach $28.50 in the next year. This suggests a possible upside of 122.0% from the stock's current price.
View analysts' price targets for Athenex
.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Amarin (AMRN), QUALCOMM (QCOM), Gilead Sciences (gild), AbbVie (ABBV), Canopy Growth (CGC) and Opko Health (OPK).

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)
  • Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.73%), Goldman Sachs Group Inc. (0.82%), Prudential Financial Inc. (0.56%), Charles Schwab Investment Management Inc. (0.46%), Nuveen Asset Management LLC (0.40%) and Point72 Asset Management L.P. (0.34%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo, Song-Yi Zhang, Stephanie A Davis and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Jaffetilchin Investment Partners LLC, Point72 Asset Management L.P., Two Sigma Advisers LP, Engineers Gate Manager LP, UBS Group AG, Nuveen Asset Management LLC, and SG Americas Securities LLC.
View insider buying and selling activity for Athenex
.

Which major investors are buying Athenex stock?

ATNX stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, Marshall Wace LLP, Vanguard Group Inc., Athanor Capital LP, Charles Schwab Investment Management Inc., Tudor Investment Corp Et Al, and Rafferty Asset Management LLC. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Stephanie A Davis, and William Wei Zuo.
View insider buying and selling activity for Athenex
.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $12.84.

How big of a company is Athenex?

Athenex has a market capitalization of $1.05 billion and generates $101.23 million in revenue each year. The company earns $-123,750,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. Athenex employs 575 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.